HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

glimepiride (Amarel)

Subscribe to New Research on glimepiride

structure given in first source

Also Known As:

Amarel; Amaryl; 1-(4-(2-(3-ethyl-4-methyl-2-oxo-3-pyrrolinecarboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)urea; Aventis Behring brand of glimepiride; Aventis Pharma brand of glimepiride; Aventis brand of glimepiride; HOE 490; HOE-490; Hoechst brand of glimepiride; Lacer brand of glimepiride; Roname; glymepiride

Networked: 325 relevant articles (40 outcomes, 106 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Urea: 9142
  - Sulfonylurea Compounds: 29
    - glimepiride: 325
- Sulfur Compounds: 135
  - Sulfones: 136
    - Sulfonylurea Compounds: 29
      - glimepiride: 325

Experts

1.	Derosa, Giuseppe: 8 articles (07/2014 - 02/2003)
2.	Forst, Thomas: 7 articles (10/2014 - 10/2005)
3.	Pfützner, Andreas: 7 articles (10/2014 - 10/2005)
4.	Derosa, G: 6 articles (12/2014 - 06/2004)
5.	Ciccarelli, Leonardina: 6 articles (05/2006 - 02/2003)
6.	Fogari, Elena: 4 articles (07/2014 - 05/2004)
7.	Perez, Alfonso: 4 articles (01/2011 - 04/2008)
8.	Ciccarelli, L: 4 articles (08/2010 - 06/2004)
9.	Ferrari, Ilaria: 4 articles (05/2006 - 05/2005)
10.	Cicero, Arrigo F G: 4 articles (05/2006 - 05/2004)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 12/01/2012 - "Therefore, glimepiride nanosuspensions can be expected to gain considerable attention in the treatment of type 2 diabetes mellitus due to its improved therapeutic activity." 05/01/2014 - "Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension." 04/14/2012 - "TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial." 01/01/2003 - "The goal of this study was to evaluate the efficacy and safety of glimepiride, a long-acting sulfonylurea, as an adjunct to diet/exercise in Mexican Americans with type 2 diabetes mellitus. " 01/01/2003 - "Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study."
2.	Insulin Resistance 11/01/2005 - "We can conclude that the association of a thiazolinedione to the glimepiride treatment of type 2 diabetic subjects with metabolic syndrome is associated to a significant improvement in the long-term blood pressure control, related to a reduction in insulin-resistance." 02/01/2005 - "Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone." 02/01/2006 - "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." 06/01/2005 - "In conclusion, switching conventional SUs to glimepiride reduced insulin resistance without improving glycemic control. " 02/01/2003 - "Glimepiride remarkably improved insulin resistance, suggested by a significant reduction in HOMA-IR, an increase in MCR-g, and a reduction in HbA(1c) without changing extrapancreatic beta-cell function and urine CPR. "
3.	Body Weight (Weight, Body) 03/01/2015 - "At baseline, overall mean age was 58.5 years, body weight 68.1 kg, duration of diabetes 6.9 years and daily glimepiride dose 3.3 mg. " 01/01/2014 - "CANA 100 and 300 mg reduced body weight by 3.7 and 4.0 kg, respectively compared to a 0.7 kg increase with glimepiride. " 11/01/2011 - "The second and third subgroups were orally administered 0.1 mg kg(-1) body weight/day glimepiride and 250 mg kg(-1) body weight/day Nerium oleander, respectively for 4 weeks. " 04/01/2010 - "Most active extracts were further studied to dose-dependent (200, 100, and 50 mg/kg body weight (bw)) hypoglycemic and antihyperglycemic effects alone and in combination with glimepiride (20, 10, and 5 mg/kg bw). " 07/01/2003 - "Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study."
4.	Weight Gain 05/01/2006 - "The long-term observations of 2 patients with a CYP2C91/3 suggested that subjects with a CYP2C91/3 respond well to glimepiride during the initial phase of treatment, but 1 patient have shown the weight gain over the long-term treatment. " 01/01/2003 - "More weight gain was seen with glimepiride compared with placebo. " 01/01/2012 - "In clinical studies, glimepiride was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. " 03/01/2003 - "In clinical studies, glimepiride was generally associated with a lower risk of hypoglycemia and less weight gain than other SUs. " 07/01/2001 - "Outside of Japan, several clinical studies have demonstrated that glimepiride shows less hypoglycemia and no weight gain. "
5.	Hypoglycemia (Reactive Hypoglycemia) 03/27/2015 - "All but one patient no longer experienced hypoglycemia after discontinuing glimepiride. " 12/01/2014 - "The analysis indicates that the previously reported results are not driven by high doses of glimepiride and points to interesting differences among patients regarding the susceptibility to hypoglycemia with sulfonylureas." 04/01/2014 - "Although, severe hypoglycemia did not occur, symptomatic hypoglycemia was more frequent in glimepiride group (P = 0.01). " 12/01/2013 - "Importantly, fasiglifam was comparable to placebo with regards to the incidence of hypoglycemia and it produced significantly fewer episodes compared with glimepiride. " 03/01/2011 - "Therefore, overdose of glimepiride by ingestion of the Chinese dietary supplements appears to be associated with the development of prolonged hypoglycemia."

Related Drugs and Biologics

1.	Metformin (Glucophage)
2.	Insulin (Novolin)
3.	liraglutide
4.	pioglitazone (Actos)
5.	Glyburide (Glibenclamide)
6.	rosiglitazone (Avandia)
7.	BI 1356
8.	2- (3- (4- ethoxybenzyl)- 4- chlorophenyl)- 6- hydroxymethyltetrahydro- 2H- pyran- 3,4,5- triol
9.	glargine (insulin glargine)
10.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Cardiopulmonary Resuscitation (CPR)
3.	Angioplasty (Angioplasty, Transluminal)
4.	Diet Therapy (Therapy, Diet)
5.	Injections